Extended Data Fig. 6: Change in pro-inflammatory cytokine levels according to spleen response ( ≥ 35% reduction in spleen volume).
From: Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
Figure shows the mean relative difference in inflammatory cytokine changes from baseline at week 24 in patients with spleen response compared to patients without spleen response. Data are presented as mean relative difference ± 95% CI. For exploratory endpoints, we report descriptive statistical analyses only. *NF-κB set included B2M, CRP, CD40-L, hepcidin, IL-6, IL-12p40, MIP-1 beta, MPIF-1, RANTES, TNFR2, TNF, VCAM-1. B2M, beta-2 microglobulin; CI, confidence interval; CRP, C-reactive protein; IL, interleukin; MIP, macrophage inflammatory protein; MPIF, myeloid progenitor inhibitory factor; NF-κB, nuclear factor kappa B; RANTES, regulated upon activation, normal T cell expressed and secreted; TNF, tumor necrosis factor; TNFR, TNF receptor; VCAM, vascular cell adhesion protein.
